A5040479075- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 detection and testing
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- Viral gastroenteritis research and epidemiology
- Bacillus and Francisella bacterial research
- Viral Infections and Immunology Research
- HIV Research and Treatment
- T-cell and B-cell Immunology
- Microfluidic and Bio-sensing Technologies
- Immunotherapy and Immune Responses
- Bacteriophages and microbial interactions
- Influenza Virus Research Studies
- Computational Drug Discovery Methods
- Immune Cell Function and Interaction
- Pulmonary Hypertension Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- RNA and protein synthesis mechanisms
- Respiratory viral infections research
- Diagnosis and treatment of tuberculosis
- interferon and immune responses
- Congenital heart defects research
Columbia University
1998-2025
Aaron Diamond AIDS Research Center
2021-2025
Columbia College
2024-2025
Royal College of Physicians
2024-2025
Nanjing University of Chinese Medicine
2024-2025
Nanjing Medical University
2025
Qingdao University
2024-2025
Yuhuangding Hospital
2024-2025
Second Affiliated Hospital of Nanjing Medical University
2024
Columbia University Irving Medical Center
2018-2022
The identification of the Omicron (B.1.1.529.1 or BA.1) variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana November 2021
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization BQ.1, BQ.1.1, XBB, XBB.1 by sera vaccinees infected persons was markedly impaired, including individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against were lower 13- 81-fold 66- 155-fold, respectively, far beyond what had been observed date. Monoclonal antibodies...
Abstract SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have surged notably to become dominant in the United States South Africa, respectively 1,2 . These new carrying further mutations their spike proteins raise concerns that they may evade neutralizing antibodies, thereby compromising efficacy of COVID-19 vaccines therapeutic monoclonals. We now report findings from a systematic antigenic analysis these surging subvariants. is only modestly (1.8-fold) more resistant sera vaccinated...
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 (refs. 1,2). However, because SARS-CoV-2 evolved become resistant other therapeutic modalities3-9, there is a concern that same could occur for nirmatrelvir. Here we examined this possibility by in vitro passaging nirmatrelvir using two independent approaches, including one on large scale. Indeed, highly viruses emerged from both and their sequences showed...
The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this rest on development effective interventions. Single combination monoclonal antibody (mAb) therapeutics have received emergency use authorization 1–3 , with more in pipeline 4–7 . Furthermore, multiple vaccine constructs shown promise 8 including two ~95% protective efficacy against 9,10 However, these interventions were directed toward initial SARS-CoV-2 that emerged...
Abstract The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this rest on development effective interventions. Two monoclonal antibody (mAb) therapeutics have received emergency use authorization, more are in pipeline. Furthermore, multiple vaccine constructs shown promise, including two with ~95% protective efficacy against Covid-19. However, these interventions were directed toward initial SARS-CoV-2 that emerged 2019....
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2.75 emerged recently and appears to be spreading. It has nine mutations in spike compared with the currently circulating BA.2, raising concerns that it may further evade vaccine-elicited therapeutic antibodies. We found moderately more neutralization resistant sera from vaccinated/boosted individuals than BA.2 (1.8-fold), similar BA.2.12.1 (1.1-fold), but sensitive BA.4/5 (0.6-fold). Relative showed...
The recently reported B.1.1.529 Omicron variant of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) includes 34 mutations in the spike protein relative to Wuhan strain, including 15 receptor-binding domain (RBD). Functional studies have shown substantially escape activity many SARS-CoV-2-neutralizing antibodies. Here, we report a 3.1 Å-resolution cryoelectron microscopy (cryo-EM) structure ectodomain. depicts that is exclusively 1-RBD-up conformation with high mobility RBD. Many...
To combat the evolving SARS-CoV-2 Omicron variants, bivalent COVID-19 mRNA vaccines, encoding both ancestral and BA.5 spikes, have replaced monovalent vaccines in numerous countries. However, fourth doses of either vaccine result similar neutralizing antibody titers against subvariants, raising possibility immunological imprinting. address this, we investigate responses 72 participants given three a vaccine, followed by or booster, those with breakthrough infections BQ. Bivalent boosters do...
Congenital diaphragmatic hernia (CDH) is a severe birth defect that often accompanied by other congenital anomalies. Previous exome sequencing studies for CDH have supported role of de novo damaging variants but did not identify any recurrently mutated genes. To investigate further the genetics CDH, we analyzed coding in 362 proband-parent trios including 271 new reported this study. We identified four unrelated individuals with MYRF (P = 5.3x10-8), one likely gene-disrupting (LGD) and three...
Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or N-terminal (NTD). Over a dozen neutralizing NTD-directed antibodies have been studied structurally, and all single antigenic supersite in NTD (site 1). Here, we report cryo-EM structure of potent antibody 5-7, which recognizes site distinct from other antibodies, inserting binding loop into an exposed hydrophobic pocket between two sheets β sandwich. Interestingly, this was previously identified as...
Abstract The identification of the Omicron variant (B.1.1.529.1 or BA.1) SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in Botswana November 2021 1 immediately raised alarms due to sheer number mutations spike glycoprotein that could lead striking antibody evasion. We 2 and others 3–6 recently reported results this Journal confirming such a concern. Continuing surveillance evolution has since revealed rise prevalence two sublineages, BA.1 with an R346K mutation (BA.1+R346K)...
Antibodies with heavy chains that derive from the VH1-2 gene constitute some of most potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies yet identified. To provide insight into whether these genetic similarities inform common modes recognition, we determine structures SARS-CoV-2 spike in complex three VH1-2-derived antibodies: 2-15, 2-43, and H4. All use VH1-2-encoded motifs to recognize receptor-binding domain (RBD), heavy-chain N53I-enhancing binding...
Abstract Background Pulmonary arterial hypertension (PAH) is a lethal vasculopathy characterized by pathogenic remodeling of pulmonary arterioles leading to increased pressures, right ventricular hypertrophy, and heart failure. PAH can be associated with other diseases (APAH: connective tissue diseases, congenital disease, others) but often the etiology idiopathic (IPAH). Mutations in bone morphogenetic protein receptor 2 ( BMPR2 ) are cause most heritable cases vast majority genetically...